Merck Re-Enters Oncology With Zolinza Approval For Rare Skin Cancer
Merck's oncologic Zolinza will be available mid-October at a cost of $60 per capsule, the company said following vorinostat's Oct. 6 approval for a rare skin cancer.
Merck's oncologic Zolinza will be available mid-October at a cost of $60 per capsule, the company said following vorinostat's Oct. 6 approval for a rare skin cancer.